Related Experiment Videos
[Gemcitabine-based combinations in inoperable pancreatic cancers]
Christophe Louvet1, Thierry André, Pascal Artru
1Service d'oncologie, médecine interne, Hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75012 Paris. christophe.louvet@sat.ap-hop-paris.fr
Bulletin Du Cancer
|November 27, 2002
Summary
Standard gemcitabine treatment for pancreatic cancer shows limited results. Combination therapies with gemcitabine are being studied for improved efficacy in unresectable pancreatic adenocarcinoma.
Area of Science:
- Oncology
- Medical Chemistry
Background:
- Pancreatic adenocarcinoma, particularly unresectable forms, has limited treatment options.
- Gemcitabine infusion is the current standard of care but demonstrates suboptimal outcomes.
Purpose of the Study:
- To review and summarize the efficacy of gemcitabine-based combination therapies.
- To evaluate novel treatment strategies for unresectable pancreatic adenocarcinoma.
Main Methods:
- Literature review of clinical studies combining gemcitabine with other chemotherapeutic agents.
- Analysis of efficacy data from gemcitabine combination trials.
Main Results:
- Gemcitabine combined with 5-fluorouracil (5FU), docetaxel, platinum compounds, irinotecan, and epirubicin are under investigation.
- Several gemcitabine combinations show promising efficacy compared to gemcitabine monotherapy.
Conclusions:
- Gemcitabine-based combination regimens represent a potential advancement in pancreatic cancer treatment.
- Further comparative studies are warranted to establish superior treatment protocols for unresectable pancreatic adenocarcinoma.